Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Tested positive for COVID-19 after taking booster; Lack of drug effect; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (Tested positive for COVID-19 after taking booster) and DRUG INEFFECTIVE (Lack of drug effect) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002A21A and 032120A) for COVID-19 vaccination.     Concurrent medical conditions included Food allergy (Spinach.), Hyperprolactinemia, Hashimoto's thyroiditis (hyperthyroidism), Palpitations and Vitamin D deficiency. Concomitant products included ALBUTEROL SULFATE, DICLOFENAC, ESOMEPRAZOLE, LEVOTHYROXINE SODIUM (LEVOTHYROXIN) and FLUTICASONE PROPIONATE (FLOVENT) for an unknown indication.   On 03-Feb-2021 at 10:45 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Mar-2021 at 9:45 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 27-Dec-2021, the patient experienced COVID-19 (Tested positive for COVID-19 after taking booster) and DRUG INEFFECTIVE (Lack of drug effect). At the time of the report, COVID-19 (Tested positive for COVID-19 after taking booster) and DRUG INEFFECTIVE (Lack of drug effect) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Dec-2021, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medication were reported. The patient received a 0.25 ml booster dose on 21-Dec-2021.  Company Comment: This spontaneous case concerns a female patient of unknown age with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 (with a positive SARS-CoV-2 test). Drug ineffective was also considered (COVID-19 occurred approximately 9 months post-completion of primary vaccination of mRNA-1273 within recommended interval). The event of COVID-19 occurred 6 days after the booster dose of mRNA-1273 vaccine. Patient did not have any signs and symptoms associated with the event. She did not seek medical care nor received any treatment. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-503460 (Patient Link).; Sender's Comments: This spontaneous case concerns a female patient of unknown age with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 (with a positive SARS-CoV-2 test). Drug ineffective was also considered (COVID-19 occurred approximately 9 months post-completion of primary vaccination of mRNA-1273 within recommended interval). The event of COVID-19 occurred 6 days after the booster dose of mRNA-1273 vaccine. Patient did not have any signs and symptoms associated with the event. She did not seek medical care nor received any treatment. The benefit-risk relationship of mRNA-1273 is not affected by this report.